Standard RT

RADIATION2 trials

Sponsors

University of Erlangen-Nürnberg Medical School, Groupe Oncologie Radiotherapie Tete et Cou

Conditions

Head and Neck CancerHead and Neck Squamous Cell Carcinoma

Phase 3

Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer

TerminatedNCT01126216

University of Erlangen-Nürnberg Medical SchoolHead and Neck Cancer

Start: 2010-06-30End: 2019-06-30Updated: 2021-05-04

Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC

CompletedNCT01864850

Groupe Oncologie Radiotherapie Tete et CouHead and Neck Squamous Cell Carcinoma

Start: 2013-10-18End: 2020-06-05Updated: 2023-09-22

Related Papers

Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial.

2020-02-0728 citations

Randomised phase-III-trial of concurrent chemoradiation (CRT) for locally advanced head and neck cancer (stage III-IVB): Comparing dose reduced radiotherapy (63,6 Gy) with paclitaxel/cisplatinum to standard radiotherapy (70,6 Gy) with fluorouracil/cisplatinum.

Journal of Clinical Oncology2017-05-205 citations

Elderly Head and Neck Cancer (ELAN) study: Personalized treatment according to geriatric assessment in patients age 70 or older: First prospective trials in patients with squamous cell cancer of the head and neck (SCCHN) unsuitable for surgery.

Journal of Clinical Oncology2014-05-2019 citations